Compare JMDC's index exit with other healthcare and data focused companies that are still attracting index linked capital through the list of solid balance sheet and fundamentals (21 results)
To own JMDC, you need to believe in the long term value of healthcare big data and telemedicine infrastructure in Japan, and in this company’s ability to keep turning that data into paid products for insurers, providers and drug makers. The latest FTSE All World exit mainly affects how some index funds treat the stock rather than how clients use JMDC’s platforms. In the short term, the more important levers are continued take up of its healthcare big data tools and telemedicine services, plus how efficiently those yen of revenue convert into profit.
Price action suggests the index change has not altered the overall story on its own, with the share price up over the past month and quarter despite a weaker 1 year return. Investors are still weighing a business with ¥52,342 of revenue, ¥6,930 of net income and a history of earnings growth against a relatively high P/E of 34.6x, modest return on equity and net profit margins that are slightly lower than last year. Volatile trading, expensive valuation signals and reliance on higher risk funding sources all sit alongside forecasts for faster revenue and profit expansion than the broader JP market.
That said, there is one aspect of JMDC’s profile that can easily be glossed over until you focus on ...
There's only one way to know the right time to buy, sell or hold JMDC. Head to Simply Wall St's company report for the latest analysis of JMDC's Fair Value.
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
If JMDC has caught your attention but you want a broader watchlist, using the Simply Wall St Screener can help you quickly surface other companies that fit the kind of profile you are looking for without getting lost in thousands of tickers.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com